Heterologous Prime-Boosting for HIV-1 Vaccine Responses
Author Information
Author(s): Guenaga Javier, Dosenovic Pia, Ofek Gilad, Baker David, Schief William R., Kwong Peter D., Karlsson Hedestam Gunilla B., Wyatt Richard T.
Primary Institution: Vaccine Research Center, National Institutes of Health
Hypothesis
Can heterologous prime-boost immunization strategies effectively enhance antibody responses against the HIV-1 2F5 epitope?
Conclusion
The study found that heterologous prime-boost immunization regimens can effectively focus the immune response on the HIV-1 2F5 epitope, but did not elicit neutralizing antibodies.
Supporting Evidence
- The study demonstrated that the heterologous prime-boosting regimen increased antibody responses to the 2F5 epitope.
- Incorporating a T cell helper epitope in the immunogens resulted in higher antibody titers against the 2F5 graft.
- Two epitope scaffolds boosted responses when primed with a more immunogenic scaffold.
Takeaway
Scientists are trying to make vaccines better by using different shots to help the body recognize and fight off HIV better.
Methodology
The study used a series of immunizations in mice with different epitope scaffolds to measure antibody responses.
Limitations
The study did not achieve neutralizing antibody responses against HIV-1 despite effective B cell responses.
Participant Demographics
Adult female C57BL/6 mice were used for the immunization experiments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website